Silencing a Gene-Silencer May Unlock the Key to New Cancer Drugs
Silencing a Gene-Silencer May Unlock the Key to New Cancer Drugs
Deep inside our cells, a molecular machine called PRC2 is responsible for determining cell specialization. Researchers have now uncovered how PRC2 switches genes on and off, with the help of RNA. This breakthrough could pave the way for new treatments for difficult-to-treat cancers. By using cryo-electron microscopy, scientists were able to capture detailed images of PRC2 in action, shedding light on its mechanisms.
Understanding PRC2’s Role in Cell Development
PRC2, or polycomb repressive complex 2, is crucial for proper cell development and maintaining cell identity. Previous research has shown that PRC2 acts as a gene-silencer, shutting off access to specific regions of the genome. This study reveals the mechanisms behind PRC2’s gene regulation, providing insights into how cells differentiate into specific types. This understanding could have implications for the development of therapeutics for cancers such as blood, pancreatic, and colon cancer.
Unveiling PRC2’s Mechanisms with Cryo-Electron Microscopy
In collaboration with Nobel Laureate Thomas Cech, scientists used cryo-electron microscopy to capture high-resolution 3D images of PRC2 in action. This technique involves freezing samples at extremely cold temperatures to preserve their structure and then using an electron beam to create detailed images. By visualizing PRC2’s activity, researchers gained valuable insights into how it functions, providing a foundation for future drug development targeting PRC2 in cancer treatment.
